Group items tagged

The Pharmacists' Defence Association (PDA) has expressed disappointment at the omission, once again, of the promised Employment Rights Bill omitted from the Queen's Speech earlier this week. The Bill is pledged to strengthen day one employment rights and increase the productivity of businesses. It set out plans which would protect and enhance workers' rights and aim to make the UK the best place in the world to work at. This included plans to introduce the right to request flexible working for around 2.2 million people in Great Britain - regardless of time served in a bid to modernise the way employees work. The PDA said: "The Employment Rights Bill would have presented an opportunity to improve the ability for workers to obtain redress in the event of poor treatment or discrimination through the development of a single labour market enforcement body. "Poor employment practices, such as insecure work through long-term zero-hours contracts, unilaterally changing workers' terms and conditions by terminating their contracts and re-hiring them on new terms and conditions (also known as fire and rehire), and the sacking of workers without notice, as recently demonstrated by P & O Ferries, could have been outlawed under new legislation."

The Royal Pharmaceutical Society has opened a survey which asks its members how they would want to take part in and learn about decisions made by the RPS. The RPS said the survey was a core part of the independent review of member participation and communications led by communications consultancy Luther Pendragon. It said: "We will be asking our members to join focus groups to give their opinions on how participation can be developed and strengthened, and how RPS communications about decisions it has taken on behalf of the profession through its governance boards can be improved. We will also be asking our elected members and key external stakeholders for their views over the coming weeks." The Luther team will then build a series of recommendations for RPS and develop a corporate communications strategy which will include action plans to enable greater participation. RPS president Claire Anderson said: "We want to hear from as many of you as possible through our survey to inform how the organisation works with and engages with you, our members.

The Department of Health and Social Care (DHSC) has published plans to amend current pharmacy legislation on dispensing errors and clarify how registered pharmacies are governed. The Department's response to a public consultation on rebalancing medicines legislation and pharmacy regulation programme first proposed in summer 2018 was delayed due to Brexit and the Covid-19 pandemic. The programme aims to clarify and strengthen the organisational governance arrangements of registered pharmacies, specifically to define and clarify the core purpose of the Responsible Pharmacist and Superintendent Pharmacist roles. It will also give the General Pharmaceutical Council (GPhC) powers to define in professional standards how those roles are fulfilled.

The voter turnout in England for the Royal Pharmaceutical Society's English Pharmacy Board election dropped to 7.9 per cent this year. Out of a total of 19,512 eligible individuals, only 1,534 decided to vote. The RPS English Board received ten nominations for five vacancies this year; therefore an election was conducted. One nomination was received for the three vacancies on the Welsh Pharmacy Board. Three nominations were received for the three vacancies on the Scottish Pharmacy Board. Therefore, no election was conducted in pharmacy boards in Wales or Scotland. RPS president Claire Anderson said: "It's disappointing that the voter turnout in England has dropped to 7.9 from 11.8 per cent in 2021. We have now appointed an independent review of how RPS members, elected members and stakeholders can feel more engaged and empowered to influence RPS decisions, and eagerly await its recommendations." The Society appointed communications agency Luther Pendragon to lead a review into how it can develop and strengthen member participation.

The Pharmacists Defence Association (PDA) has welcomed the government's action of publishing 'AI Regulation White Paper' which will regulate the artificial intelligence (AI) system used in pharmacy on Wednesday (29 March). The Association had raised concerns about the risk of patient harm due to inappropriate use of so-called AI to include that seen in some of the pharmacy systems undertaking clinical checks. For some time, it has been receiving concerns from practicing pharmacists describing examples of the potentially detrimental impact of automation and online pharmacy provision on patient safety and pharmacy practice. As a result, it raised these concerns with regulators, Chief Pharmaceutical Officers, and parliamentarians in all four nations of the UK to urge action. It said: "This is required not only to protect patients, but also the frontline pharmacists who could be blamed for potential harm caused by inappropriate use of so called 'AI' systems implemented by their employer." The PDA therefore, welcomes the announcement from the UK government that they intend to strengthen regulation of such technology, empowering existing regulators to come up with tailored, context-specific approaches that suit the way AI is actually being used in their sectors; this will include pharmacy.

Chiesi Farmaceutici, the international, research-focused biopharmaceuticals and healthcare group has acquired Amryt Pharma, a global biopharmaceutical company dedicated to developing novel treatments for rare diseases. More than 300 million people worldwide are affected by rare diseases, including those who are living with ultra-rare metabolic and dermatologic conditions who still have no approved treatment. The acquisition reinforces Chiesi's commitment to deliver innovative treatments to patients with highly unmet medical needs. As a benefit corporation and a B Corp, Chiesi strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. Chiesi's Head of Chiesi Global Rare diseases Giacomo Chiesi commented: "We are excited to add the Amryt family to our company in this acquisition that demonstrates our commitment to rare diseases and aligns with our growth strategy through partnerships beyond internal research and development." Chiesi's new CEO Giuseppe Accogli said: "By joining forces and expertise we will be able to grow our capabilities and further strengthen our position to provide a positive impact on patients living with rare diseases." With regard to the financing of the deal, cash consideration has been partially financed through a EUR 700m syndicated loan led by BNP Paribas and Crédit Agricole as Global Coordinators and ESG Structuring Banks, acting alongside BPER and Deutsche Bank as Mandated Lead Arrangers. Crédit Agricole is Loan Agent too. Lenders have been advised by Clifford Chance, while Baker and McKenzie has assisted Chiesi Farmaceutici.

AAH Pharmaceuticals (AAH) has announced the appointment of Brain Chambers as Chief Commercial Officer. "I'm proud to lead the commercial functions in AAH in my new role and broader area of responsibility." Said Brian. "I'm committed to delivering on great value for our customers and building and strengthening our supplier partnerships." Brain is associated with AAH Pharmaceuticals for more than 14 years. He joined the organisation as Business Development Manager in October 2008. His previous role in the organisation was on Sales and Marketing Director. He posted on LinkedIn: "This is a big move for me personally, but that's a side hustle. What is the main play here is AAH becoming a standalone independent wholesale business focussed on only the AAH customer and our core business and this is just one part of that.

The UK government on Thursday (8 May) launched a new plan to tackle antimicrobial resistance (AMR), a global issue that makes infections difficult or impossible to treat. This is the second phase of a series of 5-year national action plans, aimed at supporting the government's 20-year vision to contain and control AMR by 2040. With the launch of this new national action plan, the UK commits to reducing its use of antimicrobials - such as antibiotics, antifungals and antivirals - in humans and animals. Additionally, it aims to strengthen surveillance of drug-resistant infections before they emerge and incentivise industry to develop the next generation of treatments. There are also plans to expand initiatives such as the world-first 'subscription model' for antimicrobials, launched in 2019 as a pilot.

The UK Health Security Agency (UKHSA) and The Pirbright Institute have launched a new collaboration to develop vaccines against henipavirus, a genus of viruses that includes Nipah virus. Funded by the Medical Research Council, this research aims to develop a vaccine that provides cross protection against the whole genus, addressing the threat of outbreaks from new or emerging henipaviruses and strengthening epidemic preparedness. Scientists at UKHSA will evaluate the protective efficacy of vaccines developed by The Pirbright Institute by using use a model of Nipah virus disease, which mimics the infection in humans. Professor Isabel Oliver, chief scientific officer at UKHSA, stated that the study would improve understanding of henipaviruses and enhance efforts to protect health from this "current and future global health threat." "The work will also make a vital contribution to the 100 Days Mission - an important initiative to make sure the world is better prepared for the next pandemic by accelerating the development of diagnostics, therapeutics and vaccines," he added.

British Pharma giant, GSK is planning to invest more than £200 million (about $253 million) into the United Kingdom over the next two years to strengthen its manufacturing network. The money will be used to improve the pharmaceutical group's UK sites, including construction of new facilities and assembly lines, The Daily Mail first reported on Sunday. GSK has already earmarked £67 million to upgrade its manufacturing site in Montrose, Scotland, where a new production facility is being constructed. The upgrade is expected to help boost its production of active pharmaceutical ingredients (API) for the future supply of medicines. Regis Simard, head of global supply chain, told the publication that their six UK manufacturing sites, including Montrose, are an important part of their global manufacturing network.

Welcome to our comprehensive guide on understanding and managing musculoskeletal pain. This type of discomfort, often arising from an injury to the body's muscles, joints, tendons, ligaments, or nerves, can lead to significant functional impairment and reduced quality of life. In the following sections, we'll delve into the causes, diagnosis, and various treatment options for musculoskeletal pain, equipping you with the knowledge you need to manage and alleviate your symptoms effectively. Consult a Medical Professional While this guide offers a general understanding of musculoskeletal pain, it is critical to consult with a healthcare professional for any pain or discomfort you may be experiencing. Health practitioners can offer a proper diagnosis and develop a personalized treatment plan that considers your specific symptoms, condition, and overall health. For example, the best physical therapists can suggest a variety of exercises and stretches to help strengthen muscles and alleviate pain. Some pain may require surgery, while others can be managed with medication or physical therapy. Your medical provider will work with you to find the most effective treatment plan.

A new bill was introduced to Parliament on Wednesday (20 March) to prohibit the sale of tobacco to children under the age of 15, delivering on the Prime Minister's commitment to create a smokefree generation. The Tobacco and Vapes Bill aims to protect future generations from the harmful impacts of smoking, thereby saving thousands of lives and billions of pounds for the NHS. The bill will also introduce new powers to restrict vape flavours and packaging deliberately targeted towards children, as well as allow the government to change how they are displayed in shops, moving them out of sight of children and away from products that appeal to them, like sweets. Additionally, enforcement officers' powers will be strengthened with 'on the spot fines' of £100 to ensure compliance with the new laws. This complements the existing maximum fine of £2,500 that local authorities can already impose. It will also become illegal to provide free samples of vapes to children under the age of 18.

The professional leadership body for pharmacists has urged the General Pharmaceutical Council's (GPhC) to make it mandatory to have a chief pharmacist within organisations to ensure transparency for patients, the public and pharmacy staff. On 23 January, the GPhC launched a consultation seeking views on the new draft Standards for Chief Pharmacists it has developed to strengthen pharmacy governance. These standards outlined the professional responsibilities and qualifications required by a chief pharmacist to support their organisation and its staff to deliver "safe and effective" pharmacy services. The pharmacy regulator highlighted the importance of having a registered chief pharmacist meeting these standards in hospitals (or relevant settings) to benefit from the new legislation regarding accidental errors. In response to the consultation, the RPS expressed that while meeting these standards could enhance pharmacy governance, they may not provide the framework needed to fully support staff in reporting and learning from errors.

Seven NHS trusts in England are set to begin trials of new wireless technologies to help improve patient care and strengthen connectivity in A&Es and ambulance bays. They have been awarded around £1 million as part of NHS England's Wireless Trials programme, which aims to leverage advanced wireless technologies to enhance patient care and experiences while freeing up more staff time. Manchester University NHS Foundation Trust will introduce an innovative approach of combining satellite and cloud-based wireless solutions to enhance connectivity across its 10 hospital sites and wider community services. At Mid Cheshire and Princess Alexandra Hospital NHS trusts, wireless trackers will be installed on medical equipment and hospital beds. This will allow real-time monitoring and location tracking, enabling easy accessibility for staff to locate necessary items promptly.

Global logistics company, JAS has received the Wholesale Distribution Authorisation (WDA(H)) license from the UK's Medicine and Healthcare Products Regulatory Agency (MHRA) for its Pharma and Healthcare Division. In a press release issued on Thursday (22 February), the company said that securing the license empowers its UK healthcare division to "seamlessly connect" with its more than 40 GDP (Good Distribution Practice) certified overseas stations, strengthening its capabilities for handling pharmaceutical shipments. Headquartered in Atlanta, Georgia, USA, the company boasts a team of over 7,000 professionals, with operations spanning over 100 countries. Adrian Frodsham, Regional Director for JAS, said that they were granted the WDA(H) license after a "stringent audit process." "JAS UK's pharma and healthcare division prides itself of offering innovative solutions for the international delivery of pharmaceutical products, further enhancing the growth of our pre-established healthcare division," he added.

The General Pharmaceutical Council (GPhC) has developed new draft Standards for Chief Pharmacists to strengthen pharmacy governance. It has set out the professional responsibilities as well as described the knowledge, conduct, and performance required by a chief pharmacist (or equivalent) to support their organisation and its staff to deliver "safe and effective" pharmacy services. The pharmacy regulator has also launched a consultation to find out what patients, carers, and members of the public think about the new draft standards. Participants can share their views "if there are any settings in which the standards could not be applied or met and any positive or negative impacts of the proposals," it said. The survey will open for 12 weeks, from 23 January to 16 April 2024.

With more than half of the UK population experiencing gum problems and many not believing their condition warrants treatment, there is a significant need for an oral care range that promotes good gum health and prevents future issues. Corsodyl is set to launch a new Gum Strength & Protect line, featuring two toothpastes and a daily mouthwash which are clinically proven to protect against gum problems. This range aims to meet the growing consumer demand for oral care solutions that help proactively manage gum health and prevent issues related to poor oral hygiene. The Corsodyl Gum Strength & Protect line is designed to strengthen the gum seal around teeth, offering long-lasting protection. The product is enriched with hyaluronic acid, a key building block for strong gums, and includes IPMP (Isopropyl Methylphenol) and zinc as antibacterial active ingredients.

"Raise awareness of pharmacies as places of primary health care provision," advocates the International Pharmaceutical Federation (FIP), emphasising the need for universal recognition of pharmacists as essential healthcare professionals. Despite significant advancements in pharmacy practice, many policymakers and members of the public still view pharmacies primarily as commercial enterprises rather than essential providers of healthcare services. The FIP is leading a campaign to change this perception, advocating for pharmacies to be recognised as vital components of primary health care. Primary health care is crucial for achieving "health for all." In 2018, the Declaration of Astana saw governments recommit to strengthening primary health care to achieve universal health coverage. FIP, a signatory to this declaration, has since been dedicated to enhancing the role and impact of pharmacies in primary health care.

With the UK General Election set for 4 July, pharmacy bodies are actively engaging with all political parties to secure support for the community pharmacy sector. They are pressing parties to address urgent issues such as pharmacy closures and medicine shortages. "The upcoming general election is a critical opportunity for us to strengthen supporters of community pharmacy in readiness for the new Parliament," said Janet Morrison, chief executive of Community Pharmacy England (CPE). She stressed the need for unity within the sector in advocating for community pharmacy and raising awareness of the issues with election candidates from all parties. As the general election approaches, CPE has called upon all political parties to support pharmacies by "introducing a long-term sustainable funding model and reviewing the medicines supply chain, including much-needed short-term relief measures."

Released on Monday morning, the election manifesto shared by the Liberal Democrats pledges to "strengthen patients' rights" by tackling public health inequalities and providing early access to community services. The Liberal Democrats Party's manifesto promises to address the issues at both the "front and back doors" of the National Health Service (NHS), which the party claims has been plunged into crisis by the Conservatives. Pledging to invest in public health and early access to community services, the party aims to "work towards a fairer and more sustainable long-term funding model for pharmacies and build on the Pharmacy First approach to give patients more accessible routine services and ease the pressure on GPs." The pledge also includes making prescriptions for people with chronic mental health conditions free on the NHS, as part of a wider commitment to review the entire schedule of exemptions for prescription charges.